The following report provides detailed analysis of Mergers and Acquisitions of BioPharma and Pharmaceuticals companies u...
A Shifting Landscape: The Bio Industry's May 2024 Layoffs May 2024 witnessed a wave of layoffs across the bio industry,...
March 2024 has been marked by a series of layoffs in the biotech and pharmaceutical sector, raising concerns and drawing...
In February, the Biotech and BioPharma industries faced a wave of strategic layoffs, signaling a significant shift towar...
Growth and innovation in the global life sciences industry has analysts predicting the market size will increase by clos...
IESE Business School releases today a new report on corporate venturing in deep tech in East and Southeast Asia, which f...
Pharma 4.0 concepts are taking hold in pharmaceutical manufacturing. The industry's unique characteristics are driving i...
Hong Kong's The South China Morning Post announced the launch of China Digital Health Report 20...
The hepatitis C virus (HCV) therapeutics market in Japan is highly competitive with stiff competition between Gilead and...
Rapid expansion of digital healthcare for the provision of delivery, medical support, and intervention through mobile te...
Hong Kong-based Sihuan Pharmaceutical Holdings Group Ltd. announced that on 26 August 2020, the Company granted a t...
The market for graft versus host disease (GvHD) prophylaxis and treatment in the five growth markets (5GM*) in the Asia-...
As analytics continues to guide and drive the world’s response to COVID-19, SAS debuts the final instalment of its...
Following the announcement that Renalytix AI’s KidneyIntelX™ platform will be used to assess the risk o...
Ventilator shortages are a critical reality as the COVID-19 outbreak continues to worsen globally. According to GlobalDa...
There is currently 445 chimeric antigen receptor (CAR-T cell) therapies under development by companies headquartered acr...
The Duterte administration is implementing a three-pronged strategy to mitigate the social and economic impact of t...
The pneumococcal vaccines market is expected to grow from $5.11bn in 2018 to $6.24bn in 2028 across ...
